Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Denas, G."'
Autor:
Cavallari, I., Maddaloni, E., Gragnano, F., Patti, G., Antonucci, E., Calabro, P., Cirillo, P., Gresele, P., Palareti, G., Pengo, V., Pignatelli, P., Marcucci, R., Moscarella, E., Cesaro, A., Grossi, G., Berteotti, M., De Rosa, G., Taglialatela, V., Digitale, L., Denas, G., Pastori, D., del Pinto, M., Fierro, T.
Publikováno v:
Internal and Emergency Medicine. 16:1583-1591
The risk of ischemic events carried by different clusters of type 2 diabetes mellitus (DM) in the setting of secondary prevention is not definite and the association between DM and bleeding complications is controversial. We explored these issues in
Autor:
Patti, G., Cavallari, I., Andreotti, F., Calabrò, P., Cirillo, P., Denas, G., Galli, M., Golia, E., Maddaloni, E., Marcucci, R., Parato, V. M., Pengo, V., Prisco, D., Ricottini, E., Renda, G., Santilli, F., Simeone, P., De Caterina, R., on behalf of the Working Group on Thrombosis of the Italian Society of Cardiology
Publikováno v:
Nature Reviews. Cardiology
Diabetes mellitus is an important risk factor for a first cardiovascular event and for worse outcomes after a cardiovascular event has occurred. This situation might be caused, at least in part, by the prothrombotic status observed in patients with d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::925fb1178918c6755ac6959ef825277d
http://hdl.handle.net/11568/1097340
http://hdl.handle.net/11568/1097340
Autor:
Pengo V, Denas G, Bison E, Banzato A, Sp, Jose, Gresele P, Marongiu F, Erba N, Veschi F, Ghirarduzzi A, Erica De Candia, Montaruli B, Marietta M, Testa S, Barcellona D, Tripodi A, Italian Federation of Thrombosis Centers (FCSA)
Publikováno v:
Europe PubMed Central
Objective Anti-prothrombin (aPT) antibodies have been found in Lupus Anticoagulant (LA) positive patients. Their prevalence and relative contribution to thromboembolic risk in LA-positive patients is not well defined. The aim of this study was to det
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe35cdaeb3f152997d01da09dc1b9868
http://europepmc.org/abstract/med/20542544
http://europepmc.org/abstract/med/20542544
Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure
Autor:
Elena Silvestri, Maria Gerosa, Gentian Denas, Doris Barcellona, Tiziana Fierro, Valeria De Micheli, Laura Andreoli, Angelo Ghirarduzzi, Alberto Tosetto, Paolo Gresele, Ariela Hoxha, Vittorio Pengo, Ida Martinelli, Arturo Cafolla, Domenico Prisco, Sophie Testa, Angela Tincani, Anna Falanga
Background: Trial of Rivaroxaban in AntiPhospholipid Syndrome was a prospective randomized, open-label, noninferiority study conducted in 14 centers in Italy. Rivaroxaban was compared with warfarin for the prevention of thromboembolic events, major b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e1c6bd624d8976d32fdc25017cf9751
http://hdl.handle.net/11577/3394474
http://hdl.handle.net/11577/3394474
Autor:
Daniele Pastori, Paolo Gresele, Marzia Conte, Arturo Cesaro, Ferdinando Carlo Sasso, Gentian Denas, Giuseppe Patti, Pia Clara Pafundi, Gualtiero Palareti, Paolo Calabrò, Plinio Cirillo, Emilia Antonucci, Fabio Fimiani, Tiziana Fierro, Luigi Di Serafino, Elisabetta Moscarella, Vittorio Pengo, Camilleri Eleonora, Ilaria Cavallari, Pasquale Pignatelli, Rossella Marcucci, Felice Gragnano, Maurizio Del Pinto
The protective effect of obesity on mortality in acute coronary syndromes (ACS) patients remains debated. We aimed at evaluating the impact of obesity on ischemic and bleeding events as possible explanations to the obesity paradox in ACS patients. Fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61e9504a6c1e9b83efb24d05422b49b8
http://hdl.handle.net/11588/842476
http://hdl.handle.net/11588/842476
Autor:
Angelo Ghirarduzzi, Seena Padayattil Jose, Domenico Prisco, Arturo Cafolla, Maria Gerosa, Angela Tincani, Tiziana Fierro, Sophie Testa, Doris Barcellona, Caterina Cenci, Ariela Hoxha, Vittorio Pengo, Ida Martinelli, Amelia Ruffatti, Giacomo Zoppellaro, Paolo Gresele, Laura Andreoli, Alberto Tosetto, Gentian Denas, Alessandra Banzato, Valeria De Micheli, Anna Falanga
Rivaroxaban is an effective and safe alternative to warfarin in patients with atrial fibrillation and venous thromboembolism. We tested the efficacy and safety of rivaroxaban compared with warfarin in high-risk patients with thrombotic antiphospholip
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d9cf57903737e167f05da27b8771756
http://hdl.handle.net/11577/3294717
http://hdl.handle.net/11577/3294717
Autor:
Sabino Iliceto, Martino F. Pengo, Paolo Prandoni, Franco Noventa, Gentian Denas, Anna Maria Grion, Umberto Gallo, Vittorio Pengo
Publikováno v:
Blood. 117:1707-1709
Whether long-term use of vitamin K antagonists (VKAs) might affect the incidence of cancer is a longstanding hypothesis. We conducted a population-based study including all cancer- and thromboembolism-free patients of our health area; study groups we